特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
474979

造影剤腎症治療薬:パイプライン製品の分析

Contrast Induced Nephropathy - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 46 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
造影剤腎症治療薬:パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 46 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、造影剤腎症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、休止中・中止されたプロジェクトなどに関する情報を提供しています。

イントロダクション

  • 調査範囲

造影剤腎症 - 概要

造影剤腎症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

造影剤腎症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

造影剤腎症の治療薬開発に従事している企業

造影剤腎症 - 薬剤プロファイル

造影剤腎症 - 休止中のプロジェクト

造影剤腎症 - 開発が中止された製品

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Contrast Induced Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Contrast Induced Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
  • Contrast Induced Nephropathy - Pipeline by Pharming Group NV, H2 2020
  • Contrast Induced Nephropathy - Pipeline by Radikal Therapeutics Inc, H2 2020
  • Contrast Induced Nephropathy - Pipeline by Saghmos Therapeutics Inc, H2 2020
  • Contrast Induced Nephropathy - Dormant Projects, H2 2020
  • Contrast Induced Nephropathy - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Contrast Induced Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12435IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy - Pipeline Review, H2 2020, provides an overview of the Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline landscape.

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25%increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 μmol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles,puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure. Treatment includes electrolyte management.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 3 and 1 respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Contrast Induced Nephropathy - Overview
  • Contrast Induced Nephropathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Contrast Induced Nephropathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Contrast Induced Nephropathy - Companies Involved in Therapeutics Development
  • Daiichi Sankyo Co Ltd
  • Pharming Group NV
  • Radikal Therapeutics Inc
  • Saghmos Therapeutics Inc
  • Contrast Induced Nephropathy - Drug Profiles
  • carperitide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • conestat alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • R-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Contrast Induced Nephropathy - Dormant Projects
  • Contrast Induced Nephropathy - Discontinued Products
  • Contrast Induced Nephropathy - Product Development Milestones
  • Featured News & Press Releases
  • Oct 17, 2018: Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST) in Contrast-induced Nephropathy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.